JLE

European Journal of Dermatology

MENU

Safety of secukinumab in psoriasis patients with latent tuberculosis infection Volume 30, numéro 6, November-December 2020

Tableaux

Auteurs
1 Department of Dermatology, Centro Hospitalar Universitário do Porto, Porto, Portugal
2 Department of Infectious Diseases, Centro Hospitalar Universitário do Porto, Porto, Portugal
3 Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal

Tuberculosis (TB) has always represented a concern in the setting of systemic treatment for psoriasis, mainly with biologic therapy. Currently, latent tuberculosis infection (LTBI) treatment is mandatory in all patients starting biologic therapy [1]. Data suggest a variable risk of TB reactivation in patients with LTBI depending on the mechanism of action of treatment, even for agents within the same class [1]. Moreover, toxicity associated with LTBI treatment is considerable [2]. Isoniazid remains [...]